EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease

Sanjana Parikh, Kei Irie, Ryota Tanaka, Takanobu Nadai, Phillip Minar, Tomoyuki Mizuno

Clinical Pharmacokinetics · 2026

DOI: 10.1007/s40262-026-01682-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2026. Verfasst von Sanjana Parikh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Models, Biological, Inflammatory Bowel Diseases, Gastrointestinal Agents. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases, Japan Research Foundation for Clinical Pharmacology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Vedolizumab is a gut-selective, humanized monoclonal antibody that binds to α4β7 integrin, preventing lymphocyte trafficking to the intestinal mucosa. While approved for adults with moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD), drug exposure may vary significantly with disease activity. Physiologically based pharmacokinetic (PBPK) modeling provides a mechanistic framework to integrate drug properties with system physiology, enabling the prediction of pharmacokinetics (PK) under these various pathophysiological conditions. In this study, we developed a minimal mechanistic PBPK model incorporating target-mediated drug disposition (TMDD) to characterize the PK of healthy adults and patients with varying inflammatory bowel disease severity.

Methods

A minimal PBPK model incorporating TMDD was developed for vedolizumab using the Simcyp Simulator. The model was parameterized with literature values for healthy adults, verified against clinical PK data from healthy volunteers, and adapted for patients with varying disease severity by estimating target abundance ( R _max) to reflect α4β7 upregulation in active inflammation. Model performance was assessed by comparing simulated and observed concentration–time profiles and predicted-to-observed (P/O) ratios for peak concentration ( C _max), area under the curve from time 0 to time of the last concentration (AUC_0– tlast ), and trough concentration ( C _trough).

Results

The PBPK model demonstrated robust predictive performance across varying disease states and ethnicities, compared with reported PK parameters in clinical studies. In healthy adults, mean P/O ratios for C _max and AUC_0– tlast ranged from 0.81 to 1.11 and 0.80 to 1.02, respectively, across single doses of 0.2–10 mg/kg. For patients with mild-to-moderate UC, the estimated R _max yielded mean P/O ratios for C _max and AUC_0– tlast of 0.88–1.02 and 0.78–0.99, respectively. Additionally, for moderate-to-severe UC and CD, mean P/O ratios for C _trough fell within 0.67–1.49. Simulations indicated that higher R _max values increased clearance and reduced systemic exposure, with mean predicted C _trough in high target-expression groups frequently falling below the efficacy thresholds of 12 μg/mL and 14 μg/mL.

Conclusions

This study presents the first PBPK model for vedolizumab that quantitatively captures disease-related α4β7 upregulation and its impact on PK in adults. The model provides a mechanistic basis for simulating exposure across disease states and supports model-informed precision dosing strategies to optimize treatment outcomes in UC and CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedModels, BiologicalInflammatory Bowel DiseasesGastrointestinal AgentsHumansAdultFemaleMaleMiddle AgedYoung AdultIntegrinsHealthy Volunteers

Substanzen

Antibodies, Monoclonal, HumanizedvedolizumabGastrointestinal AgentsIntegrinsintegrin alpha4beta7

Autor:innen und Institutionen

  • Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA.
  • Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan.
  • Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. Tomoyuki.Mizuno@cchmc.org.

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Japan Research Foundation for Clinical Pharmacology

Zitieren

APA

Parikh, S., Irie, K., Tanaka, R., Nadai, T., Minar, P., & Mizuno, T. (2026). Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-026-01682-w

Vancouver

Parikh S, Irie K, Tanaka R, Nadai T, Minar P, Mizuno T. Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease. Clinical Pharmacokinetics. 2026. doi:10.1007/s40262-026-01682-w

BibTeX
@article{Parikh2026,
  author = {Parikh, Sanjana and Irie, Kei and Tanaka, Ryota and Nadai, Takanobu and Minar, Phillip and Mizuno, Tomoyuki},
  title = {Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  doi = {10.1007/s40262-026-01682-w}
}
Kostenlos starten →